(September 25, 2020, 9:35 AM EDT) -- WASHINGTON, D.C. — The U.S. Department of Justice (DOJ) announced Sept. 23 that Gilead Sciences Inc. has agreed to pay $97 million to resolve allegations that it violated the False Claims Act's Anti-Kickback Statute (AKS) by setting up a 501(c)(3) foundation that it used to make insurance copayments for Medicare patients who used its pulmonary arterial hypertension drug Letairis....